Valuation: UCB

Market Cap 42.29B 48.81B 39.62B 36.14B 67.94B 4,655B 68.99B 466B 182B 2,331B 183B 179B 7,773B P/E 2026 *
22.2x
P/E 2027 * 18.3x
Enterprise Value 42.77B 49.37B 40.07B 36.55B 68.72B 4,709B 69.78B 471B 184B 2,358B 185B 181B 7,861B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4.18x
Free-Float
61.59%
Yield 2026 *
0.66%
Yield 2027 * 0.68%
1 day-0.74%
1 week-3.44%
Current month-1.65%
1 month-7.08%
3 months-7.78%
6 months-20.01%
Current year-6.64%
1 week 219.1
Extreme 219.1
228.8
1 month 214.2
Extreme 214.2
251.4
Current year 214.2
Extreme 214.2
289.5
1 year 189.6
Extreme 189.6
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.96
Extreme 54.96
289.5
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-3.44% - - 48.81B
+0.87%+4.28%+43.38%-0.40% 79.68B
-3.73%+3.89%-1.33%+25.77% 50.61B
-0.90%-2.31%+15.50%+167.59% 48.81B
-0.66%+3.90%-48.98%-47.71% 46.91B
+0.41%+1.61%+55.04%-23.15% 30.86B
+1.76%+18.82%+137.99%-36.01% 25.42B
-0.54%+1.71%+40.26%+84.56% 24.48B
-0.42%+5.37%+8.99%+187.03% 21.2B
-1.26%+0.16%+64.61%+162.85% 16.39B
Average -0.54%+3.56%+35.05%+57.84% 38.26B
Weighted average by Cap. -0.56%+3.17%+26.98%+41.49%

Financials

2026 *2027 *
Net sales 8.69B 10.03B 8.14B 7.42B 13.96B 956B 14.17B 95.74B 37.42B 479B 37.65B 36.83B 1,597B 9.69B 11.18B 9.08B 8.28B 15.57B 1,067B 15.81B 107B 41.74B 534B 41.99B 41.08B 1,781B
Net income 1.93B 2.22B 1.8B 1.65B 3.09B 212B 3.14B 21.22B 8.29B 106B 8.34B 8.16B 354B 2.33B 2.69B 2.18B 1.99B 3.74B 256B 3.8B 25.65B 10.03B 128B 10.09B 9.87B 428B
Net Debt 482M 557M 452M 412M 775M 53.11B 787M 5.32B 2.08B 26.59B 2.09B 2.05B 88.67B -1.8B -2.08B -1.69B -1.54B -2.89B -198B -2.93B -19.82B -7.75B -99.14B -7.79B -7.63B -331B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
13/08/26 221.05 -0.20% 2
12/08/26 €222.53 -1.39% 325,448
11/08/26 €225.67 +0.22% 13,305
10/08/26 €225.17 -0.51% 19,288
07/08/26 €226.32 -1.13% 50,964
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
221.80EUR
Average target price
285.26EUR
Spread / Average Target
+28.61%

Quarterly revenue - Rate of surprise